Claims for Patent: 7,384,765

Summary for Patent: 7,384,765

Title:	Cell culture performance with betaine
Abstract:	This invention relates generally to the field of cell culture. More particularly, the invention relates to improving viability of recombinant cell cultures and the yields of secreted polypeptides therefrom by the addition of betaine to the tissue culture medium.
Inventor(s):	Follstad; Brian D. (Seattle, WA), Potter; Anne H. (Sammamish, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	11/437,418
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,384,765
Patent Claims:	1. A method comprising culturing a recombinantly engineered cell line in culture medium in normal osmotic conditions, wherein the cell line is recombinantly engineered to express a polypeptide of interest, the medium has an effective amount of betaine, whereby cell survival and expression of said polypeptide of interest are improved relative to cells grown without betaine, wherein the cells are grown during a proliferative phase in the absence of betaine, and in the presence of betaine in an induction phase. 2. The method of claim 1 wherein the cell line is a non-animal cell line. 3. The method of claim 1 wherein the cell line is a prokaryotic cell line. 4. The method of claim 3 wherein the prokaryotic cell line is an E. coli cell line. 5. The method of claim 2 wherein the cell line is an insect cell line. 6. The method of claim 5 wherein the insect cell line is an Sf9 cell line. 7. The method of claim 2 wherein the cell line is a plant cell line. 8. The method of claim 2 wherein the cell line is a yeast cell line. 9. The method of claim 1, wherein the betaine is selected from the group consisting of glycine betaine and betaine aldehyde. 10. The method of claim 9, wherein the betaine is at a concentration of about 20 mM. 11. The method of claim 10, wherein the polypeptide of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble flt3 ligand, a soluble CD40 ligand, an erythropoietin, an antibody, an Fc-fusion protein, a calcitonin, a growth hormone, an insulin, an insulinotropin, insulin-like growth factors, a parathyroid hormone, an interferons, a nerve growth factor, a glucagons, an interleukins, a colony stimulating factor, a glucocerebrosidase, a superoxide dismutase, a tissue plasminogen activator, a Factor VIII, a Factor IX, an apolipoprotein E, an Apolipoprotein A-I, a globin, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, and an alpha-galactosidase A. 12. The method of claim 11, wherein the cell line is cultured in a bioreactor. 13. The method of claim 11, further comprising collecting the protein of interest. 14. The method of claim 11, wherein the cell line is grown in suspension culture.

Details for Patent 7,384,765

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-08-23